MDxHealth 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Q3 2026 revenue from continuing operations was $22.7 million, flat compared to Q3 2025; 79% came from tissue-based tests versus 92% in the prior-year period, reflecting the integration of ExivDx liquid testing.
- Gross profit was $14 million, down 5% from $14.8 million, and gross margin was 61.8% versus 65%, primarily due to a shift toward liquid-based volume following the ExivDx acquisition.
- Operating expenses increased 16% to $22.2 million, resulting in an operating loss of $8.1 million versus $4.4 million in Q3 2025. Net loss from continuing operations increased 26% to $12.3 million from $9.7 million, and adjusted EBITDA was negative $6.3 million versus negative $0.9 million.
- Cash and cash equivalents totaled $31.7 million as of September 30th, 2026. Financial metrics exclude Resolve, which remains classified as a discontinued operation after its strategic wind-down and the cessation of Plano, Texas laboratory operations prior to June 30th.
- Management attributed Q3 results falling short of expectations to accelerated sales-team turnover following the discontinuation of Resolve, which disrupted commercial execution.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Please note this call is being recorded, and we are standing by if you should need any assistance. It is now my pleasure to turn the meeting over to John Fraunces with LifeSci Advisors.
Please go ahead. Before we begin, I would like to remind everyone that the company will make forward-looking statements during today's call.
Whether in prepared remarks or during the Q&A session, these forward-looking statements are subject to inherent risks and uncertainties. These risks and uncertainties are detailed in the risk factors section of the company's filings with the Securities and Exchange Commission, specifically in the company's annual report on Form 20-F. I will now turn the call over to Michael McGarrity, Chief Executive Officer.
Thanks, John. Thank you all for joining us for our third quarter 2026 earnings conference call. With me today is Ron Kalfus, Interim Chief Financial Officer. Since I joined MDxHealth, we have been consistent in our commitment to transparency, operating discipline, and our core principles of focus, execution, and growth. While our third quarter results fell short of our expectations, that commitment remains unchanged. Simply put, our Q3 results reflected temporary disruption in our commercial execution, driven by accelerated turnover within our sales organization following the discontinuation of Resolve, which was catalyzed by aggressive targeting from outside recruiters. While our disciplined commercial process has served as the foundation of our forecast accuracy and consistent performance over the past four years, that process was clearly disrupted by this recent impact on our sales force.
Importantly, we do not believe these factors represent a change in the credibility and reputation we have built with our customer base, the underlying clinical demand for our products, or our long-term market opportunity. However, as I have noted before, you are defined not by what happens to you, but how you respond. In direct response to this challenge, we have initiated a comprehensive restructuring of our commercial organization designed to reset our focus and process across our sales, marketing, and client services groups. As part of this reorganization, we have eliminated the chief commercial officer role and have effectively split our sales and marketing functions into two distinct operating groups, both of which will report directly to me. Splitting our sales and marketing groups provides clear delineation and direct accountability for product strategy and sales execution, while simultaneously enhancing the overall customer experience.
Based on my prior experience operating under this exact model, separating these functions establishes a vital check and balance on what had become a vertical operating structure, giving direct visibility into both territory-level execution and commercial strategy. Over the past several weeks, we have made considerable progress in backfilling and rebuilding our sales team, and we are highly encouraged by the caliber of talent and industry experience we are attracting to MDxHealth. Selection, development, and retention are the foundational pillars of our process through this commercial reset. With the rigor we are applying to our recruiting and onboarding, we expect to exit the fourth quarter with a fully staffed sales organization positioned to return to growth in 2027.
Across the rest of the organization, our laboratory, revenue cycle management, and administrative teams continue to focus relentlessly on supporting our commercial organization under our core mandate of quality first and customers always. We remain deeply proud of our team's commitment and resilience, not only in navigating this commercial transition, but also to what matters most, the patient and family on the other side of every sample we receive. I will follow up with some closing comments and our view forward into 2027, but first let me turn the call over to Ron to walk through our third quarter financial results.
Ron? Thank you, Mike. Before diving into our Q3 financials, I want to remind investors that following the strategic wind-down of our Resolve UTI business and the cessation of our Plano, Texas laboratory operations prior to June 30, the Resolve business remains formally classified as a discontinued operation.
Consistent with our reporting last quarter, all Q3 and prior year financial metrics discussed today reflect only our continuing core operations, with the historical results of the Resolve business fully excluded and represented. Our revenue from continuing operations for the third quarter ended September 30, 2026, was $22.7 million, which was flat compared to the third quarter of 2025. Revenue in the third quarter was comprised of 79% from tissue-based tests, compared to 92% for the same period last year, reflecting the strategic integration of ExoDx liquid testing into our core offering.
Moving below the revenue line, our gross profit for the quarter was $14 million, a decrease of 5% compared to $14.8 million for the third quarter of 2025. Gross margins were 61.8% compared to 65% for Q3 2025. This reduction of 3.2 percentage points is primarily attributed to the shift in our test mix towards liquid-based volume following the ExoDx acquisition. Our operating expenses for the quarter increased by 16% to $22.2 million. This resulted in an operating loss of $8.1 million for the quarter, compared to $4.4 million for the third quarter of 2025. This increase in operating loss was primarily driven by the expanded footprint, headcount, and operating expenses related to the ExoDx acquisition, which were not present in our baseline run rate at this time last year.
Our net loss from continuing operations increased 26% to $12.3 million, compared to $9.7 million for the prior year, again, driven by the acquired operating expenses from ExoDx. Adjusted EBITDA for the third quarter was a negative $6.3 million, compared to a negative $0.9 million for the third quarter of 2025. As always, a reconciliation of IFRS to non-IFRS financial measures is provided in the tables included in today's press release. Finally, turning to the balance sheet, our cash and cash equivalents as of September 30, 2026, totaled $31.7 million. This concludes my overview of the financial results, and I will now turn the call back to Mike.
Thanks, Ron. As we look forward, we are confident that the commercial reset we have undertaken is both necessary and timely. By fortifying our sales organization and establishing direct accountability across sales and marketing, we are ensuring that our commercial engine is operating at full strength as we enter a catalyst-rich period in 2027. Specifically, we continue to leverage the strength of our peer-reviewed ProMPT data in advance of our landmark ProtecT trial in collaboration with the University of Oxford, which carries the potential to transform the market landscape for GPS in the active surveillance setting. Furthermore, we remain on track to roll out our strategic AI initiatives in the first half of 2027, which will build on the evidence-based excellence of our precision diagnostics and deliver meaningful incremental value to both our urology and pathology stakeholders. This company has a proven track record of execution.
We remain confident in and fully committed to returning to the exemplary level of sales execution that has been the hallmark of our results over the past four years. We are confident that we are well-positioned to return MDxHealth to sustained top-line growth and operating profitability. We remain a growth company focused exclusively on urologic cancers, and we will continue to build our unmatched vertical of clinically actionable precision diagnostics, Confirm, GPS, and Exo mdx, for our customers and patients across the entire prostate cancer continuum. As always, we carry a profound responsibility to all of our stakeholders, including our patients, clinicians, payers, and shareholders. Thank you for your continued interest in and support of MDxHealth, and I will now turn the call over to the operator for questions.
Thank you. If you'd like to ask a question, press star one on your keypad. To leave the queue at any time, press star two. Once again, that is star one to ask a question. We'll take our first question from Thomas Flaten with Lake Street Capital. Your line is now open.
Hey, good afternoon, guys. I appreciate you taking the questions. First question, with respect to the restructuring of the commercial organization, was there something specific that you were trying to address, Mike, or was it more of just a general reinvigoration of the team?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
8 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
